In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 1 to 10 of 11

Sort by

Keyword or reference number: multiple myelomaRemove Keyword or reference number: multiple myeloma filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]	Technology appraisal guidance	TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212	Technology appraisal guidance	5 March 2025
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211	Technology appraisal guidance	19 March 2025
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]	Technology appraisal guidance	TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]	Technology appraisal guidance	TBC
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026]	Technology appraisal guidance	11 December 2024
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981	Technology appraisal guidance	16 July 2025
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]	Technology appraisal guidance	TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]	Technology appraisal guidance	TBC
Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments ID5082	Technology appraisal guidance	TBC

Results per page

10
25
50
All